VitaDAO’s Post

🌟 Exciting Week in Biotech Investments! 🌟 This week has been remarkable for the biotech industry, with top investments targeting not only diverse modalities but also diverse indications. 🚀💡The influx of capital showcases the industry's commitment to addressing a wide range of medical needs and is a great sign for the future of healthcare. #Biotech #Investments #Innovation #Healthcare #GeneTherapy #CellTherapy #CancerTreatment #TCR #FutureOfHealth #Immunotherapies

An in-depth look at what could be a once-in-a-generation move. https://lnkd.in/d-ie9zpZ

Indaptus Therapeutics Initiates #Unrestricted Enrollment of Patients on Decoy20 Weekly Dosing Based on Encouraging Safety Data Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical stage #biotechnology company dedicated to pioneering #innovative #cancer and #viralinfection treatments, provides an update regarding key clinical advancements in its Phase 1 trial of lead drug candidate Decoy20.  The Safety Review Committee examined weekly administration data at the lower Decoy20 dose and cleared unrestricted enrollment of patients at this dose. The safety profile observed to date remains aligned with Decoy20’s expected mechanism of action. The most clinically relevant treatment-related adverse events include Grade 2 Infusion Related Reaction and Grade 2 Hypotension, both of transient duration. “Unrestricted enrollment of patients at the lower Decoy20 dose will enable us to gather more safety and efficacy data, which is crucial for assessing the full potential of Decoy20. The data will guide how we initiate combination therapy next year, a critical phase in advancing Decoy20,” said Dr. Roger Waltzman, Indaptus Chief Medical Officer. Jeffrey Meckler, Chief Executive Officer, added, “We continue to gather robust data on Decoy20, which remains consistent with our expectations from preclinical studies. We believe the continuation of this trial, and the eventual initiation of combination therapy studies presents an important opportunity to have a potentially significant impact on cancer immunotherapy. We look forward to sharing these results in the coming months.”

Simulations Plus Acquires Pro-ficiency, Creating One-of-a-Kind Platform Spanning the Drug Development Continuum I wanted to let you know the exciting news that Pro-ficiency has been acquired by Simulations Plus (SLP).   Simulations Plus is a leading provider of modeling and simulation software and consulting services supporting drug discovery, development, research, and regulatory submissions. We are excited to join forces with a company that shares our commitment to good science, our passion for leveraging advanced technologies to advance critical research, and our dedication to supporting clients in improving their ROI on drug development and patient care. Each of our companies brings unique strengths to the table, and I am confident that together we will see increased growth and success. Both companies leverage simulation technology to accelerate the performance of Life Science companies from discovery to delivery of new therapeutics. Simluations Plus focuses on quantitative simulation and modeling services. Pro-ficiency leverages experiential simulation to elevate the performance of life science teams. The combination creates a one-of-a-kind simulation platform spanning the drug development continuum. Pro-ficiency has shown exceptional growth since the investment by QHP Capital in February of 2021. This $100M transaction provided exception returns to the QHP LPs and Pro-ficiency founders in a timeline just over the ideal holding window of 36 months. I want to thank our employees and customers for creating and supporting the Pro-ficiency journey. Thanks also to QHP Capital that trusted me with guiding this investment for the firm. I am personally excited to join the Simulations Plus team as President. In the coming days, I will sharing some lessons learned for fellow entrepreneurs. https://lnkd.in/evQe-NVM #Simulations-Plus #Pro-ficiency #Simulation

What do you think about this article 🌞❓

Why work with multiple reviews providers when Advarra offers comprehensive services? We’ll help you simplify your study oversight – learn more:

Check out our new application note covering the use of the SuperScript IV Template-Switching RT Master Mix in post-vaccination immune repertoire profiling. The application note discusses how the master mix aids in gene expression profiling, enabling the synthesis of full-length cDNA and reducing amplification biases. It also highlights a study that demonstrates the use of the SuperScript IV Template-Switching RT Master Mix for immune repertoire analysis following influenza vaccination. Learn more now!

Our latest article.

More GLPA news! There was #SUSTAIN 6 and then now #SOUL! New Data from #SOUL study for oral #semaglutide showing 14% reduction of Cardio Vascular events in people with type 2 diabetes and established CV disease and/or CKD Watch the space for STRIDE! #diabetes #heart #cardiovascular #drug #obesity #endocrinology #endocrinologist Novo Nordisk #research #trials